TY - JOUR
T1 - Good research practices for measuring drug costs in cost-effectiveness analyses
T2 - Medicare, medicaid and other US Government payers perspectives: The ISPOR drug cost task force report - Part IV
AU - Mullins, C. Daniel
AU - Seal, Brian
AU - Seoane-Vazquez, Enrique
AU - Sankaranarayanan, Jayashri
AU - Asche, Carl V.
AU - Jayadevappa, Ravishankar
AU - Lee, Won Chan
AU - Romanus, Dorothy K.
AU - Wang, Junling
AU - Hay, Joel W.
AU - Smeeding, Jim
PY - 2010
Y1 - 2010
N2 - Objectives: Public programs finance a large share of the US pharmaceutical expenditures. To date, there are not guidelines for estimating the cost of drugs financed by US public programs. The objective of this study was to provide standards for estimating the cost of drugs financed by US public programs for utilization in pharmacoeconomic evaluations. Methods: This report was prepared by the ISPOR Task Force on Good Research Practices - Use of Drug Costs for Cost-Effectiveness Analysis Medicare, Medicaid, and other US Government Payers Subgroup. The Subgroup was convened to assess the methodological and practical issues confronted by researchers when estimating the cost of drugs financed by US public programs, and to propose standards for more transparent, accurate and consistent costing methods. Results: The Subgroup proposed these recommendations: 1) researchers must consider regulation requirements that affect the drug cost paid by public programs; 2) drug cost must represent the actual acquisition cost, incorporating any rebates or discounts; 3) transparency with respect to cost inputs must be ensured; 4) inclusion of the public program's perspective is recommended; 5) high cost drugs require special attention, particularly when drugs represent a significant proportion of health-care expenditures for a specific disease; and 6) because of variations across public programs, sensitivity analyses for actual acquisition cost, real-world adherence, and generics availability are warranted. Specific recommendations also were proposed for the Medicare and Medicaid programs. Conclusions: As pharmacoeconomic evaluations for coverage decisions made by US public programs grows, the need for precise and consistent estimation of drug costs is warranted. Application of the proposed recommendations will allow researchers to include accurate and unbiased cost estimates in pharmacoeconomic evaluations.
AB - Objectives: Public programs finance a large share of the US pharmaceutical expenditures. To date, there are not guidelines for estimating the cost of drugs financed by US public programs. The objective of this study was to provide standards for estimating the cost of drugs financed by US public programs for utilization in pharmacoeconomic evaluations. Methods: This report was prepared by the ISPOR Task Force on Good Research Practices - Use of Drug Costs for Cost-Effectiveness Analysis Medicare, Medicaid, and other US Government Payers Subgroup. The Subgroup was convened to assess the methodological and practical issues confronted by researchers when estimating the cost of drugs financed by US public programs, and to propose standards for more transparent, accurate and consistent costing methods. Results: The Subgroup proposed these recommendations: 1) researchers must consider regulation requirements that affect the drug cost paid by public programs; 2) drug cost must represent the actual acquisition cost, incorporating any rebates or discounts; 3) transparency with respect to cost inputs must be ensured; 4) inclusion of the public program's perspective is recommended; 5) high cost drugs require special attention, particularly when drugs represent a significant proportion of health-care expenditures for a specific disease; and 6) because of variations across public programs, sensitivity analyses for actual acquisition cost, real-world adherence, and generics availability are warranted. Specific recommendations also were proposed for the Medicare and Medicaid programs. Conclusions: As pharmacoeconomic evaluations for coverage decisions made by US public programs grows, the need for precise and consistent estimation of drug costs is warranted. Application of the proposed recommendations will allow researchers to include accurate and unbiased cost estimates in pharmacoeconomic evaluations.
KW - Cost study
KW - Drug cost
KW - Medicaid
KW - Medicare
KW - Pharmacoeconomic
UR - http://www.scopus.com/inward/record.url?scp=72949123739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72949123739&partnerID=8YFLogxK
U2 - 10.1111/j.1524-4733.2009.00604.x
DO - 10.1111/j.1524-4733.2009.00604.x
M3 - Article
C2 - 19807903
AN - SCOPUS:72949123739
VL - 13
SP - 18
EP - 24
JO - Value in Health
JF - Value in Health
SN - 1098-3015
IS - 1
ER -